News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

May 19, 2025

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

STOCKHOLM, Sweden, 19th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached “Database Lock” in its clinical development program. The next step is statistical analyses of the data to compile…

May 9, 2025

Lipidor AB (publ) publishes annual report for 2024

STOCKHOLM, Sweden, 9th May 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the…

March 17, 2025

Lipidor announces all patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the…

February 28, 2025

Lipidor AB (publ) publishes year-end report for 2024

STOCKHOLM, Sweden, 28th February 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the…

January 21, 2025

Lipidor announces half of patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 21st January 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients…

December 3, 2024

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall…

November 20, 2024

Lipidor publishes CEO statement for the quarter: “Study results expected by the end of Q1 2025”

STOCKHOLM, Sweden, 20 November 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business…

September 24, 2024

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has…

August 28, 2024

Lipidor AB (publ) publishes interim report for Q2 2024

STOCKHOLM, Sweden, 28 August 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…

August 20, 2024

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

STOCKHOLM, Sweden, 20th August 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the clinical trial material…

July 1, 2024

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW…